Recently, Kangweijian Biopharmaceutical Co., Ltd. (hereinafter referred to as "Kangweijian"), a leading company in China's synthetic biology field, has successfully completed its Series B financing. This round of financing was jointly participated by several investment institutions, including DCH VGC, Orient Jiafu, Kweichow Maotai, and PuHua Capital. The funds raised will mainly be used to expand production capacity, optimize the R&D system, and accelerate the commercialization process of products to meet the growing market demand for high-quality biopharmaceutical products.CDH VGC participated in the layout during Comviq Health's Series A financing, and continued to increase its investment in this Series B round.，Reflects its firm confidence in the originality of Comviq's underlying technology, its ability to commercialize and implement, as well as its international market positioning.
Kangweijian, established in 2019, is a national high-tech enterprise located in Shenzhen, Guangdong Province. The company focuses on providing safe and high-quality products and services to the global food, cosmetic ingredients, dietary supplement ingredients, pharmaceutical excipients, and animal nutrition industries.Relying on its self-developed "Ester Enzymatic Synthesis Process Technology Platform," Combi-Blocks has become a global leader in the biocatalytic enzyme production of Ascorbyl Palmitate (AP).，AndAP, as an important food additive and cosmetic raw material, continues to see strong market demand.
ComviHealth adopts an enzymatic synthesis process,The production process is more green and environmentally friendly,This core technology platform achieves full-process green and environmentally friendly production, with a designed annual output of 3000 tons.Can。The annual production of the first phase of its Huizhou production base has reached 1,200 tons.Breaking the monopoly pattern of traditional chemical synthesis methods, it is currently the world's largest bio-enzymatic AP production line.
As a core product, Convyjian's Ascorbyl Palmitate is a highly effective antioxidant widely used in food, health products, cosmetics, and pharmaceuticals. Additionally, Convyjian continues to advance the research, development, and production of new products such as Phytosterol Esters and Vitamin A Palmitate. The company has obtained multiple international certifications including ISO9001, US-FDA, HALAL, and KOSHER, ensuring its products maintain global market competitiveness.Gao Jieliang, Senior Partner of CDH VGC, stated"DCH VGC has long been focusing on breakthrough innovations in the biomanufacturing field. We believe that synthetic biology is not only a paradigm revolution at the technical level but also a core driving force for the global industry to transition towards being green and efficient. By independently developing 'zero-emission' enzymatic ester synthesis technology, Convision has set a world-leading process benchmark in the niche field of ascorbyl palmitate, demonstrating systematic capabilities from research to mass production and from a single product to diversified applications. It is precisely the kind of company that represents new productive forces in our eyes."CDH VGC has invested in numerous outstanding companies in the field of synthetic biology, including Zhiyu Biotech, Ruijia Kang, Rongrui Technology, and Graineron.DingHui VGC believes that synthetic biology, by reconstructing traditional production pathways through foundational technologies, combines the advantages of green sustainability and cost efficiency, and will bring profound changes to the fields of materials, energy, and medicine in the future.
